Atlas Trials

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Clinical trial NCT03263637 · COMPLETED

Trial details

NCT number
NCT03263637
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaHigh Risk Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaRichter's SyndromeB-cell Non-Hodgkin LymphomaT-cell Non-Hodgkin LymphomaSmall Lymphocytic LymphomaMultiple Myeloma
Start date
2017-10-24
Primary completion
2021-09-30
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.